// App-Quantinova.ai

: Associations of TACSTD2/TROP2 and NECTIN-4/NECTIN-4 with molecular subtypes, PD-L1 expression and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts.

Researchers

Presenter

  • Veronika Bahlinger

Principal Investigators

  • Pamela Strissel

  • Reiner Strick

  • Fabienne Lange

  • Carol-Immanuel Geppert

  • Niklas Klümper

  • Michael Hölzel

  • Sven Wach

  • Helge Taubert

  • Danijel Sikic

  • Bernd Wullich

  • Miriam Angeloni

  • Fulvia Ferrazzi

  • Lauri Diehl

  • Maria Kovalenko

  • Emon Elboudwarej

  • Juliane Margarete Juergensmeier

  • Arndt Hartmann

  • Markus Eckstein

Medical Centers

  • Institute of Pathology and Neuropathology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany

  • Department of Urology, University Hospital Bonn, University of Bonn, Bonn, Germany

  • Gilead Sciences, Inc., Foster City, CA

  • Cardiology and Angiology, University Hospital Erlangen, Erlangen, Germany

  • Institute of Experimental Oncology, University Hospital Bonn, Bonn, Germany

Locations

  • Germany

  • United States

Companies

  • Gilead Sciences, Inc

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Bladder Cancer

Biomarkers

  • Programmed death-ligand 1

  • Fibroblast growth factor receptor 3

Drug/Treatment

  • IMMU132

  • Enfortumab vedotin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved